Oral GLP-1 Orforglipron Reduced Sleep Apnea Events in Trials
Data presented at the American Heart Association Scientific Sessions shows fewer nocturnal breathing interruptions and lower blood pressure over one year.
Trial Results Presented at the American Heart Association
Adults with moderate-to-severe obstructive sleep apnea (OSA) and excess weight had fewer breathing interruptions during sleep after taking the experimental oral glucagon-like peptide-1 (GLP-1) medication orforglipron for one year.
The preliminary findings come from two large randomized trials presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago by lead author Dr. Vaishnavi Kundel of the Icahn School of Medicine at Mount Sinai.
Participants taking orforglipron once per day recorded a reduction of approximately 18 breathing interruptions per hour. In comparison, participants assigned to the placebo group had a reduction of roughly five events per hour.
Measured Changes in Oxygen Drops and Cardiovascular Markers
Treatment with orforglipron led to greater reductions in sleep apnea-related drops in blood oxygen levels across both evaluated trials.
In Study 1, blood oxygen desaturation events dropped 51% in the orforglipron group compared to 18% with placebo. Study 2 showed a 44% drop with orforglipron versus an 18% drop in the placebo group.
Participants assigned to orforglipron also saw systolic blood pressure fall by roughly 7 mm Hg after one year. People receiving placebo saw average decreases between 1.7 and 2.2 mm Hg.
Weight Loss and Systemic Inflammation Outcomes
Participants taking orforglipron lost between 10% and 11% of their baseline body weight over the 52-week study period.
Placebo groups recorded average weight reductions of 1% to 2% over the same duration. Blood tests also showed larger drops in the systemic inflammation marker high-sensitivity C-reactive protein (hs-CRP), falling 42% in Study 1 and 38% in Study 2 for orforglipron participants compared to 4% and 18% in the placebo arms.
- Weight loss likely drove a significant portion of the observed relief in airway obstruction.
- The most common side effects reported were gastrointestinal symptoms, including nausea, diarrhea, and constipation.
- Patients characterized these side effects as mostly mild to moderate in severity.
Clinical Role Alongside Airway Devices
The investigators noted that orforglipron is an investigational drug that is not currently approved by regulators to treat obstructive sleep apnea.
Researchers emphasized that the medication is not intended to replace continuous positive airway pressure (CPAP) machines. Instead, data indicates the pill achieved similar improvements in breathing events among both CPAP users and non-CPAP users.
If approved by regulatory agencies, orforglipron could provide an adjunctive medical therapy to use alongside CPAP or offer an alternative for individuals unable to tolerate nocturnal airway devices.
What to Look For in a Sleep & Recovery Tracker
The Oura Ring and Whoop are the most accurate consumer options for sleep stages and HRV; a smartwatch (Apple Watch, Garmin) works too if you'd rather not wear a ring. Prioritize validated HRV and sleep-stage tracking over step counts, check whether it needs a subscription (Whoop does), and pick something comfortable enough to wear every night.


Related Articles
Study Maps Hypothalamus Shifts in Alzheimer's Disease
Researchers mapped hypothalamic subregions in Alzheimer's disease, finding distinct structural...
Read article RecoveryCluster Headache and Burnout Symptoms Linked in New Study
A Karolinska Institutet study finds two-thirds of patients in an active cluster headache phase...
Read article RecoveryBrain Waste Clearance Waves During Sleep Decline in Older Adults
MIT researchers found cerebrospinal fluid waves that clear brain waste during deep sleep are...
Read article RecoverySensory Nerves Drive Bone Mass Recovery in Unloading Study
A study in mice found sensory nerves inside bone decrease during unloading and are necessary for...
Read articleWant medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Topic updates
Get the weekly recovery roundup
Sleep, HRV, fatigue, burnout, cortisol rhythm, sleep apnea, overtraining, and stress physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.